A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

NCT07745504 · Not yet recruiting

Last updated 2026-08-26

This study is testing two different versions of an injectable medication called cagrilintide compared to a placebo in adults who are overweight or have obesity to see how it affects body weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 285 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-08 · est. completion 2027-07

Where 36 sites · Greece, Hungary, Portugal, Serbia, Sweden, United States

What this study is testing ClinicalTrials.gov NCT07745504 ↗

Description as written by the study sponsor.

The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.

Treatments tested

Cagrilintide Drug

Cagrilintide will be administered subcutaneously.
Placebo cagrilintide Drug

Placebo matched to cagrilintide will be administered subcutaneously.
Placebo semaglutide Drug

Placebo matched to semaglutide will be administered subcutaneously.

Main thing measured	Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07745504 ↗